Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2026; 32(46): 121707
Published online Dec 14, 2026. doi: 10.3748/wjg.121707
Published online Dec 14, 2026. doi: 10.3748/wjg.121707
Assessment of metabolic biomarkers associated with hepatic steatosis in Crohn’s disease
Cristina Suárez Ferrer, Jose Luis Rueda García, Eduardo Martin-Arranz, Maria Sanchez-Azofra, Joaquín Poza Cordón, Laura García-Ramírez, Department of Gastroenterology, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid 28046, Spain
Marta Abadía, Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid 28046, Spain
María Gema Crespo Sanchez, Department of Clinical Pathology, Hospital Universitario LA Paz, Madrid 28046, Spain
Antonio Olveira, Hepatology Unit, Hospital Universitario La Paz, Centro de Investigación Biomédica en Red (CIBER), Madrid 28046, Spain
Miriam Romero, Department of Gastroenterology and Hepatology, Hospital Universitario La Paz, Madrid 28046, Spain
Marta Molero-Luis, Servicio de Análisis Clínicos, Hospital Universitario La Paz, Madrid 28046, Spain
Araceli García, Hepatology Unit, Hospital Universitario La Paz, Madrid 28046, Madrid, Spain
Clara Amiama Roig, Department of Gastroenterology, Hospital Universitario La Paz, Madrid 28046, Spain
Maria Dolores Martin-Arranz, Department of Gastroenterology, School of Medicine, Universidad Autónoma de Madrid, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid 28046, Spain
Author contributions: Suárez Ferrer C contributed to conceptualization, methodology, investigation, data curation, formal analysis, writing original draft, writing review and editing; Abadía M, Rueda García JL, Olveira A, Romero M, Martin-Arranz E, Sanchez-Azofra M, García A, Amiama Roig C, Poza Cordón J, García-Ramírez L contributed to investigation, data curation, resources, writing review and editing; Crespo Sanchez MG, Molero-Luis M contributed to methodology, investigation, formal analysis, laboratory analysis of blood samples, writing review and editing; Martin-Arranz MD contributed to conceptualization, supervision, validation, writing review and editing, project administration; all authors contributed substantially to data interpretation, critically revised the manuscript for important intellectual content, and approved the final version of the manuscript.
Supported by the Luis Álvarez Grant awarded by the Instituto de Investigación Sanitaria IdiPAZ (IdiPAZ) in 2024.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Hospital Universitario La Paz (Madrid, Spain) (Approval No. PI-6155).
Informed consent statement: All study participants provided written informed consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-a checklist of items.
Data sharing statement: Technical appendix, statistical code, and dataset are available from the corresponding author upon reasonable request.
Corresponding author: Cristina Suárez Ferrer, MD, Doctor, Department of Gastroenterology, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Paseo de la Castellana 261, Madrid 28046, Spain. cristinajsuarezferrer@gmail.com
Received: March 31, 2026
Revised: April 20, 2026
Accepted: July 3, 2026
Published online: December 14, 2026
Processing time: 203 Days and 19.3 Hours
Revised: April 20, 2026
Accepted: July 3, 2026
Published online: December 14, 2026
Processing time: 203 Days and 19.3 Hours
Core Tip
Core Tip: Active Crohn’s disease is associated with a higher prevalence of steatosis and increased angiopoietin-like protein 6 and fibroblast growth factor 21 levels, suggesting inflammation-related metabolic alterations. Controlled attenuation parameter may serve as a reliable non-invasive tool for steatosis detection in Crohn’s disease, although inflammatory activity should be considered in its interpretation.